OS Therapies (OSTX), a clinical stage biopharmaceutical company, is at the forefront of
developing innovative treatments for Osteosarcoma (OS), breast cancer and other
solid tumors. With a dedicated focus on addressing the unmet need for new cancer
treatments in children and young adults, the company is making significant strides
in tackling the complexities of OS, a rare but aggressive bone cancer predominantly
affecting individuals under 40 years of age.
The company's primary initiative revolves around its lead product candidate, OSTHER2 (OST31-164), which is poised to revolutionize the treatment landscape for OS,
breast cancer, and other HER2 expressing cancers. This innovative immunotherapy
leverages a genetically modified strain of Listeria monocytogenes to specifically
target cancer cells that express HER2 p, a promising approach in the fight against
cancer that is complementary to HER2 antibody therapy such as Herceptin®.
Notably, OST-HER2 is distinct in the current landscape, as there have been no new
treatments approved by the FDA for OS in over 40 years.
In addition to OST-HER2, OS Therapies is expanding its impact with the OST-Tunable
Antibody Drug Conjugate (OST-tADC) platform. This cutting-edge technology
represents a next-generation approach in antibody-drug conjugates (ADCs),
featuring tunable pH-sensitive silicone linkers (SiLinkers™) and the potential to
deliver a range of payloads, including antibodies, chemotherapeutics, and mRNA
treatments. The OST-tADC platform is being developed to target solid tumors.
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
OS Therapies (OSTX) is a client of RedChip Companies, Inc. OSTX agreed to pay RedChip Companies, Inc. a $15,000 monthly cash fee, beginning in August 2024, for 12 months of investor awareness services. OSTX also agreed to pay RedChip a one-time one-hundred-thousand dollar fee for a 20-day national TV ad campaign scheduled to air weekdays from June 14 through July 14, 2024.
For full disclosure, visit RedChip.com/disclosures.